Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Tries Injecting New Life Into Its Strategy With A Generic Injectables Unit

This article was originally published in The Pink Sheet Daily

Executive Summary

Entering the sterile injectables business is one step in Pfizer's efforts to buttress its mature products by diversifying into niche markets.

You may also be interested in...



Pfizer's Message To Wall Street: We're Doing Things Differently Now

Exubera's failure was a defining moment for CEO Jeff Kindler, who says the episode motivated him to transform the way Pfizer makes decisions.

Pfizer's Message To Wall Street: We're Doing Things Differently Now

Exubera's failure was a defining moment for CEO Jeff Kindler, who says the episode motivated him to transform the way Pfizer makes decisions.

Pfizer Thinks Small: Partnership With Protalix On Gaucher Drug Eyes Cheaper Plant-Based Production

Pfizer's licensing deal with Protalix for global rights to the enzyme replacement therapy taliglucerase for the treatment of Gaucher disease, announced Dec. 1, signals the drug giant's interest in the orphan drug space. It also plays into the company's biosimilar strategy, given that taliglucerase will likely be positioned as a lower-cost alternative to Genzyme's Cerezyme (imiglucerase)

Related Content

Topics

UsernamePublicRestriction

Register

PS068708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel